According to BIS Research, Antibody Conjugate Oligonucleotides (ACOs) combine the gene-modulating properties of ...

A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce ...

Developed by ALX Oncology's protein engineers utilizing the Company's proprietary topoisomerase I inhibitor payload and ...

Its ability to measure neutralising antibodies can help determine the efficacy of new vaccines. Read more at straitstimes.com ...

This two-step process is designed to guide the immune response further along the path toward bnAb development by generating VRC01-class antibodies -- early immune defenses with key features of bnAbs.

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the first quarter of 2025 ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus.

ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy.

Compugen Ltd. (NASDAQ: CGEN) Q1 2025 Earnings Call Transcript May 19, 2025 Compugen Ltd. misses on earnings expectations.